Skip to main content
SpringerLink
Log in

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

E7070 is a novel sulfonamide antitumoragent that exhibits potent antitumoractivity in vitro and in vivo.This compound affects cell cycleprogression in human tumor cells. Toelucidate the mechanisms by which E7070inhibits tumor cell growth, we establishedand characterized an E7070-resistantsubline, A549/ER, from a human non-smallcell lung cancer cell line A549. Flowcytometric analyses demonstrated anincrease in G0/G1 and a decrease in S phasepopulations in cells treated with E7070 at20 or 100 μg/ml for 24 h. Longerexposure to E7070, i.e. 48 and 72 h,increased the G2/M phase fraction in A549cells. These inhibitory actions of E7070on cell cycle progression were not observedin A549/ER cells. E7070 inhibited thephosphorylation of pRb, decreasedexpressions of cyclin A, B1, CDK2, and CDC2proteins, and suppressed CDK2 catalyticactivity with the induction of p53 andp21 proteins in A549 cells but not inA549/ER cells. Taken together, theseresults suggest that E7070 exerts itsantitumor effects by disturbing the cellcycle at multiple points, including boththe G1/S and the G2/M transition, in humanlung cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yoshino H, Ueda N, Niijima J, Sugumi J, Kotake Y, Okada T, Koyanagi N, Asada M, Yoshimatsu K, Kitoh K: Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 35: 2496–2497, 1992

    Google Scholar 

  2. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H: Phase I study of E7010. Cancer Chemother Pharmacol 42: 127–134, 1998

    Google Scholar 

  3. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K: Mechanism of action for E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57: 3208–3213, 1997

    Google Scholar 

  4. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N: Preferential binding of E7010 to murine β3-tubulin and decreased β3-tubulin in E70101-resistant cell lines. Jpn J Cancer Res 89: 954–962, 1998

    Google Scholar 

  5. Owa T, Yoshino H, Okauchi T, Sugi N, Ozawa Y, Nagasu T, Fujikawa Y, Sawa Y, Kitoh K, Yoshimatsu K: A novel antitumor agent, ER-35744, targeting G1 phase. I. Drug discovery and overview of preclinical studies. Proc 9th NCI-EORTC, Ann Oncol Suppl 7: 399, 1996

    Google Scholar 

  6. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi N, Nagasu T, Koyanagi N, Kitoh K: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42: 3789–3799, 1999

    Google Scholar 

  7. Ozawa Y, Sugi N, Watanabe T, Nagasu T, Koyanagi N, Kitoh K, Yoshimatsu K: A novel antitumor agent, ER-35744, targeting G1 phase. II. Antitumor activities in vitro and in vivo. Proc 9th NCI-EORTC, Ann Oncol Suppl 7: 140, 1996

    Google Scholar 

  8. Sherr CJ: Cancer cell cycles. Science 274: 1672–1677, 1996

    Google Scholar 

  9. Meijer L: Chemical inhibitors of cyclin-dependent kinases, 1 edition, p 351–363 New York, NY: Plenum Press, 1995

    Google Scholar 

  10. Hunter T Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors, come of age. Cell 79: 573–582, 1994

    Google Scholar 

  11. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57: 1495–1501, 1997

    Google Scholar 

  12. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323–330, 1995

    Google Scholar 

  13. Nishio K, Fujiwara Y, Miyahara Y, Takeda Y, Ohmori T, Kubota N, Ohta S, Funayama Y, Ogasawara H, Ohata M, Saijo N: cis-diamminedichloroplatinum (II) inhibits p34cdc2 protein kinase in human lung-cancer cells. Int J Cancer 55: 616–622, 1993

    Google Scholar 

  14. Atherton-Fessler S, Hannig G, Piwnica-Worms H: Reversible tyrosine phosphorylation and cell cycle control. Sem Cell Biol 4: 433–442, 1993

    Google Scholar 

  15. Coleman TR, Dunphy WG: Cdc2 regulatory factors. Curr Opin Cell Biol 6: 877–882, 1994

    Google Scholar 

  16. Laird AD, Shalloway D: Oncoprotein signalling and mitosis. Cell Signalling 9: 249–255, 1997

    Google Scholar 

  17. Sterner JM, Murata Y, Kim HG, Kennett SB, Templeton DJ, Horowitz JM: Detection of a novel cell cycle-regulated kinase activity that associates with the amino terminus of the retinoblastoma protein in G2/M phases. J Biol Chem 270: 9281–9288, 1995

    Google Scholar 

  18. Kanzawa F, Sugimoto Y, Minato K, Kasahra K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanisms of resistance. Cancer Res 50: 5919–5924, 1990

    Google Scholar 

  19. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63, 1983

    Google Scholar 

  20. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, Harris CC: Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448–1451, 1995

    Google Scholar 

  21. Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A: Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther 82: 285–292, 1999

    Google Scholar 

  22. Kitagawa M, Higashi H, Suzuki-Takahashi I, Okabe T, Ogino H, Taya Y, Nishimura S, Okuyama A: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of Rb protein and cell cycle progression. Oncogene 9: 2549–2557, 1994

    Google Scholar 

  23. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibiton of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973–2978, 1996

    Google Scholar 

  24. Alessi F, Quarta S, Savio M, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E: The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibitor on CDK2 kinase activity. Exp Cell Res 245: 8–18, 1998

    Google Scholar 

  25. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527–536, 1997

    Google Scholar 

  26. Schnier JB, Gadbois DM, Nishi K, Bradbury EM: The kinase inhibitor staurosporine induces G1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclindependent kinase 2 in normal and transformed cells. Cancer Res 54: 5959–5963, 1994

    Google Scholar 

  27. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ: Cell cycle arrest and inhibiton by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081–2086, 1993

    Google Scholar 

  28. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW: Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of middle to late G1 phase of the cell cycle. J Cell Physiol 154: 7–15, 1993

    Google Scholar 

  29. Kakeya H, Onose R, Liu PC, Onozawa C, Matsumura F, Osada H: Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic. Cancer Res 58: 704–710, 1998

    Google Scholar 

  30. Deguchi A, Imoto M, Umezawa K: Inhibition of G1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor. J Biochem (Tokyo) 120: 1118–1122, 1996

    Google Scholar 

  31. Inokoshi J, Katagiri M, Arima S, Tanaka H, Hayashi M, Kim BY, Furumai R, Yoshida M, Horinouchi S, Omura S: Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem Biophys Res Commun 256: 372–376, 1999

    Google Scholar 

  32. Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM: The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors A potential mechanism for GGTI-298 antitumor activity. J Biol Chem 274: 6930–6934, 1999

    Google Scholar 

  33. Watanabe T, Sugi N, Owa T, Nagasu T, Koyanagi N, Kitoh K, Yoshimatsu K: A novel antitumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action. Proc Am Assoc Cancer Res 37: 391(A2667), 1996

    Google Scholar 

  34. Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T, Iwamoto Y, Tomonari A, Suzuki T, Usuda J, Narita N, Saijo N: Ectopic p16INK4 expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. Int J Cancer 86: 197–203, 2000

    Google Scholar 

  35. Shao R-G, Cao C-X, Shimizu T, O'Connor PM, Kohn KW, Pommier Y: Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57: 4029–4035, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacology Division, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo

    Kazuya Fukuoka, Jitsuo Usuda, Yasuo Iwamoto, Hisao Fukumoto, Takashi Nakamura, Nagahiro Saijo & Kazuto Nishio

  2. Second Department of Internal Medicine, Nara Medical University, Shijo-cho, Kashihara-city, Nara, Japan

    Kazuya Fukuoka, Takahiro Yoneda & Nobuhiro Narita

Authors
  1. Kazuya Fukuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jitsuo Usuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuo Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisao Fukumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuhiro Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nagahiro Saijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuto Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukuoka, K., Usuda, J., Iwamoto, Y. et al. Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells. Invest New Drugs 19, 219–227 (2001). https://doi.org/10.1023/A:1010608317361

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010608317361

Search

Navigation